InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by PRASAD SUYASH, Directeur Médical et Responsable de la R&D. Officer active across 2 companies, notably Taysha Gene Therapies, Inc.. Cumulatively, 4 reports have been published. Split: 0 buy · 4 sells. Total volume traded: €1.5m. Activity tracked since 29 June 2021. The latest transaction was disclosed on 5 July 2022 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations4 total
3,905 shares@ US$3.510.9% of flowCommon StockSEC:0001209191-22-041455:0
12,324 shares@ US$3.810.0026% mcap3.1% of flowCommon StockSEC:0001209191-22-040356:0
35,056 shares@ US$23.7448.0% of flowCommon StockSEC:0001209191-21-044563
35,056 shares@ US$23.740.041% mcap48.4% of flowCommon StockSEC:0001209191-21-044563:0
4 of 4 declarations
About PRASAD SUYASH
Suyash Prasad is the Chief Medical Officer and Head of R&D at Taysha Gene Therapies, Inc. He is responsible for overseeing research and development initiatives for gene therapies. Suyash plays a key role in innovation and advancing treatments aimed at improving patient outcomes. His expertise in medicine and biotechnology is essential for advancing Taysha's mission in the field of gene therapies.
